At a glance
ClinicalIndex Comparison RecordN/ACompleted· 70 enrolled
Drug / intervention
Nintedanibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Regulatory Required Non-interventional Study to Monitor the Safety and Effectiveness of Ofev(Nintedanib 150mg/100mg BID) in Korean Patients
In Brief
An observational study evaluating Nintedanib for Idiopathic Pulmonary Fibrosis. Completed, enrolled 70 participants across 22 sites.
Detailed Summary
The objectives of this study are to monitor the safety and effectiveness of Ofev in Korean patients in a routine clinical practice setting.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
202120222023202420252026
First PostedAug 2020
Enrollment StartJan 2021
Primary CompletionAug 2022
Study CompletionAug 2022
TodayJul 2026
First PostedAug 25, 2020
Enrollment StartJan 13, 2021
Primary CompletionAug 2, 2022
Study CompletionAug 18, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 5.9 years ago
Interventions
Nintedanibdrug
Nintedanib